SOAT1 and psoriasis: found that subcutaneous administration of EVs derived from UC-MSCs in mouse psoriasis-like models (50 μg) can effectively reduce the level of proinflammatory cytokines and chemokines including IL-17, IL-23, TNFα, and CCL20 and suppress the activation of DCs through inhibiting the JAK-STAT pathway (68).